Original language | English (US) |
---|---|
Pages (from-to) | 2192-2195 |
Number of pages | 4 |
Journal | Blood |
Volume | 135 |
Issue number | 24 |
DOIs | |
State | Published - Jun 11 2020 |
Externally published | Yes |
ASJC Scopus subject areas
- Biochemistry
- Immunology
- Hematology
- Cell Biology
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Blood, Vol. 135, No. 24, 11.06.2020, p. 2192-2195.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations
AU - Lucas, Fabienne
AU - Larkin, Karylin
AU - Thomas Gregory, C.
AU - Orwick, Shelley
AU - Doong, Tzyy Jye
AU - Lozanski, Arletta
AU - Lozanski, Gerard
AU - Misra, Shrilekha
AU - Ngankeu, Apollinaire
AU - Ozer, Hatice Gulcin
AU - Sampath, Deepa
AU - Thangavadivel, Shanmugapriya
AU - Yilmaz, Selen A.
AU - Rogers, Kerry A.
AU - Byrd, John C.
AU - Woyach, Jennifer A.
AU - Blachly, James S.
N1 - Funding Information: The authors are grateful to the patients who provided blood for the above studies and to The Ohio State University Comprehensive Cancer Center (OSUCCC) Leukemia Tissue Bank for sample procurement. This work was supported by National Institutes of Health (NIH) National Cancer Institute (NCI) grants 5P30CA016058-43, 5R01CA197870 (J.A.W.), and 5R35CA197734 (J.C.B.), and by a grant of equipment from StorageReview (J.S.B.). The OSUCCC Leukemia Tissue Bank was supported by NIH NCI grant P30 CA016058. Funding Information: This work was supported by National Institutes of Health (NIH) National Cancer Institute (NCI) grants 5P30CA016058-43, 5R01CA197870 (J.A.W.), and 5R35CA197734 (J.C.B.), and by a grant of equipment from Stor-ageReview (J.S.B.). The OSUCCC Leukemia Tissue Bank was supported by NIH NCI grant P30 CA016058. Funding Information: Conflict-of-interest disclosure: J.A.W. receives research funding from AbbVie, Janssen, Loxo, Karyopharm, and Morphosys, and has performed consulting for Janssen and Pharmacyclics. J.S.B. has received consulting fees from AbbVie, AstraZeneca, and KITE Pharma. K.A.R. receives research funding from Genentech, AbbVie, and Janssen and has consulted for Acerta Pharma. The remaining authors declare no competing financial interests.
PY - 2020/6/11
Y1 - 2020/6/11
UR - http://www.scopus.com/inward/record.url?scp=85086424199&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086424199&partnerID=8YFLogxK
U2 - 10.1182/blood.2019003722
DO - 10.1182/blood.2019003722
M3 - Letter
C2 - 32232486
AN - SCOPUS:85086424199
SN - 0006-4971
VL - 135
SP - 2192
EP - 2195
JO - Blood
JF - Blood
IS - 24
ER -